Fangzhou Inc (6086) Fair Value & Analysis
Healthcare · HK · Market cap HK$914M
Fair value as of: Aug 13, 2026
From 24 valuation models · updated 3 days ago
Share price −15.5% over the past month.
A solid business, but screening 60% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$0.2890). The favourable scenario is already priced in.
- Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (HK$0.1445 to HK$0.2890) leaves room in how you read the outcome.
Price vs Fair Value (2 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
25‑month range HK$0.6600 – HK$7.96 · fair‑value band HK$0.1445 – HK$0.2890 · the HK$0.7100 price screens above the HK$0.2805 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Fangzhou Inc (6086) currently trades at HK$0.7100, while our model-based Fair Value estimate is HK$0.2805, implying the stock looks roughly 60.5% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Fangzhou Inc generated revenue of HK$3.5B at a net margin of 0.3%. Revenue grew 46.8% year over year. It earns a return on equity of 8.3%. The balance sheet holds a net cash position of HK$261M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.1445 (bear case) to HK$0.2890 (bull case); at HK$0.7100, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -60%, 6086 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (HK$0.7300) versus Asset-Based (HK$0.0700). Highest evidence: Growth DCF (80).
Notify me when 6086 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 2
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Fangzhou Inc. provides online chronic disease management services in China. It operates through four segments: Online Retail Pharmacy Services; Comprehensive Medical Services; Wholesale; and Customized Content and Marketing Solutions.
Full company description
Fangzhou Inc. provides online chronic disease management services in China. It operates through four segments: Online Retail Pharmacy Services; Comprehensive Medical Services; Wholesale; and Customized Content and Marketing Solutions. The company offers services through online chronic disease management platform to address the needs of patients with chronic disease, such as hypertension, cardiovascular and respiratory diseases. It also engages in the sales of pharmaceutical and healthcare products through online retail pharmacy service platform, third-party platforms, and offline retail pharmacies; and online consultation, e-prescription, physician consultation, physical examination, and surgery service, as well as wholesale of pharmaceutical products. Fangzhou Inc. was founded in 2015 and is based in Guangzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Fangzhou Inc reported revenue of HK$3.5B in FY2025 versus HK$1.8B in FY2021, a compound +19.0%/yr. Reported net income was HK$11.8M in FY2025.
6086 screens 60% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 63 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$38.86 | HK$33.31 | -14% |
| Alibaba Health Information Technology Limited 0241 | HK$3.33 | HK$2.04 | -39% |
| Raia Drogasil S.A RADL3 | R$18.00 | R$15.58 | -13% |
| Yifeng Pharmacy Chain Co 603939 | ¥24.03 | ¥29.07 | +21% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.14 | ¥23.86 | +32% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 726.02 MXN | +57% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥13.44 | ¥10.57 | -21% |
| MedPlus Health Services Limited MEDPLUS | ₹675.05 | ₹379.25 | -44% |
| Yixintang Pharmaceutical Group 002727 | ¥12.29 | ¥9.45 | -23% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥16.51 | ¥10.05 | -39% |
Compare Fangzhou Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Fangzhou Inc (6086) overvalued or undervalued?
What is the fair value of 6086?
What is the quality score of 6086?
What is the revenue of Fangzhou Inc (6086)?
What is the net profit margin of 6086?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Fangzhou Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.